Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Invex Therapeutics Ltd. ( (AU:IXC) ) has issued an update.
Invex Therapeutics Ltd announced a change of its registered office address, now located at Level 5, 191 St Georges Terrace, Perth WA 6000. This relocation is part of compliance with ASX Listing Rule 3.14, and all other contact information remains unchanged. The announcement reflects ongoing organizational adjustments, which could have implications for its operational efficiencies and stakeholder communications.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company dedicated to the development and commercialization of Exenatide, a drug repurposed for the treatment of neurological conditions involving raised intracranial pressure. The company has trademarked this repurposed drug as Presendin™.
YTD Price Performance: 7.14%
Average Trading Volume: 22,464
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$5.64M
See more insights into IXC stock on TipRanks’ Stock Analysis page.
